Market Research Future (MRFR) has published on the “Global Delirium Market”.

the Delirium Market is estimated to register a CAGR of 5.30% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Delirium market— Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland).

Delirium Market Highlights

The global delirium market is accounted for to register a CAGR of 5.30% during the forecast period and is estimated to reach USD 0.512 Billion by 2032.

The global delirium market showcases dynamic prospects marked by notable highlights. Rapid strides in diagnostic technologies, pharmaceutical innovations, and advanced patient monitoring systems underscore the sector's potential for transformative growth. Analysts emphasize the significance of educational initiatives catering to healthcare professionals and the integration of cutting-edge technologies, including artificial intelligence, to enhance delirium management. The increasing role of telehealth solutions further amplifies opportunities, allowing for remote monitoring and timely intervention. Despite regulatory complexities, the market benefits from a robust framework of interdisciplinary collaboration, fostering advancements in clinical trials and research. Analysts stress the importance of staying abreast of evolving healthcare policies and reimbursement structures, acknowledging these as critical factors influencing market dynamics. The global delirium market, characterized by its intricate landscape and multifaceted challenges, invites industry players to contribute to the ongoing evolution of diagnostic and therapeutic solutions, promising a meaningful impact on the understanding and management of delirium on a global scale.

Segment Analysis

The global Delirium market has been segmented based on type, indication, and end user.

On the basis of type, the market is segmented into Hyperactive, Hypoactive, Mixed. The hypoactive segment was attributed to holding the largest market share in 2022 as estimated by MRFR analysts. This is due to hypoactive characterized by subdued motor activity, poses a unique challenge, necessitating specialized interventions. Pharmaceutical advancements and targeted therapeutic approaches are driving innovation in this market, providing novel treatment options. Healthcare providers are increasingly recognizing the importance of early detection and tailored interventions for hypoactive delirium, contributing to market expansion.

Further, we estimate that the market segment will continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product therapy and services.

On the basis of the diagnosis and treatment, the market is segmented into diagnosis and treatment. The diagnosis segment was attributed to holding the largest market share in 2022.

On the basis of the end user, the market is segmented into hospitals, speciality care, and research centers. The hospitals, speciality care, research centers segment is projected to have the largest market share during the forecast period.

Regional Analysis

The global Delirium market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe Delirium market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Delirium market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s Delirium market comprises of Middle East, Africa, and Latin America.

The North American Delirium market accounted for the largest market share in 2022 due to aging population and a rise in chronic illnesses, there is an increased awareness of delirium as a critical aspect of patient care. The region's well-established healthcare infrastructure and advanced medical research contribute to the growth of diagnostic and therapeutic innovations in delirium management. Hospitals and healthcare facilities across North America are integrating specialized protocols, training programs, and advanced technologies to enhance delirium diagnosis and treatment.

Moreover, the Europe market has been persistently growing owing to favorable health policies, and trend towards integrating health services in the European Delirium market.

Additionally, market factors, such as rising spending in healthcare, quickly evolving healthcare infrastructure, growing awareness regarding Delirium, and growing population in the Asia-Pacific region are driving the region’s growth.

Furthermore, the rest of the world's Delirium market is divided into the Middle East, Africa, and Latin America. As the region experiences population growth and an increase in age-related conditions, the awareness and recognition of delirium as a significant healthcare concern are on the rise. Healthcare providers in the Middle East and Africa are progressively focusing on implementing effective diagnostic and therapeutic strategies for delirium management.

Key Findings of the Study

• The global healthcare counseling market is expected to reach USD 0.512 Billion by 2032, at a CAGR of 5.84% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the rising spending in healthcare, quickly evolving healthcare, and growing population in the Asia-Pacific region.


• Based on Diagnosis and treatment, the diagnosis segment was attributed to holding the largest market in 2022, with an approximate market share of 35–40%.


• Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland).